Engene Earnings Reports

enGene saw a significant increase in operating expenses in Q2 2025, resulting in a net loss of $25.8 million. The company emphasized progress in its pivotal LEGEND trial and reaffirmed its cash runway into 2027.

enGene reported cash, cash equivalents and marketable securities of $297.9 million, which are expected to fund operations into 2027. The company also announced a BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026.

enGene Holdings Inc. announced its financial results for the third quarter ended July 31, 2024. The company's cash and cash equivalents were $257.7 million as of July 31, 2024, and expects this to fund operations into 2027. Net loss attributable to common shareholders was approximately $14.1 million, or $0.32 per share.

enGene reported its second quarter 2024 financial results, highlighting a net loss of $15.0 million, or $0.38 per share, and cash and cash equivalents of $264.8 million. The company is expanding the LEGEND study to include a cohort focused on enrollment of patients with high-risk, BCG-unresponsive papillary-only NMIBC.

enGene reported a net loss attributable to common shareholders of $10.7 million, or $0.46 per share, for the three months ended January 31, 2024. The company's cash and cash equivalents were $85.6 million as of January 31, 2024, and with the recent private placement, expects to fund operations into 2027.